107256-31-5

Basic information

• Product Name: 3-[2-(3-Chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride
• Synonyms: 3-[2-(3-CHLOROPHENYL)ETHYL]-2-PYRIDYL 1-METHYL-4-PIPERIDYL KETONE HYDROCHLORIDE;[3-[2-(3-Chlorophenyl)ethyl]-2-pyridinyl](1-methyl-4-piperidinyl)methanone hydrochloride
• CAS NO: 107256-31-5
• Molecular Formula: C20H24Cl2N2O
• Molecular Weight: 379.32
• Mol File: 107256-31-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 487.9oC at 760 mmHg
• Flash Point: 248.9oC
• Appearance: /
• Vapor Pressure: 6.6E-10mmHg at 25°C
• CAS DataBase Reference: 3-[2-(3-Chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(3-Chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride(107256-31-5)
• EPA Substance Registry System: 3-[2-(3-Chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride(107256-31-5)

Safety Data

• Hazardous Substances Data: 107256-31-5(Hazardous Substances Data)

Usage

General Description

3-[2-(3-Chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride is a complex organic chemical compound involving multiple functional groups. It exhibits a ketone group, a chloride group, a piperidyl group, a pyridyl group, as well as an aromatic phenyl group substituted with a chlorine atom. In this chemical, a KLK1 inhibitor, the 3-chlorophenyl group is bonded with an ethyl group, which is attached to the pyridyl group. The piperidyl group, which has an additional methyl substitution, is also attached to the ketone functionality. Due to the complexity and specificity of this compound, its potential applications could range from biochemical research to pharmaceutical development, depending upon its reactivity, stability, and biological activity. The compound exists in the form of a hydrochloride salt, which suggests its potential solubility in polar solvents or its use in reactions that require a hydrochloric acid catalyst.

InChI:InChI=1/C20H23ClN2O.ClH/c1-23-12-9-17(10-13-23)20(24)19-16(5-3-11-22-19)8-7-15-4-2-6-18(21)14-15;/h2-6,11,14,17H,7-10,12-13H2,1H3;1H

Upstream product

• 31255-57-9 3-[2-(3-chlorophenyl)ethyl]-2-pyridine-carbonitrile 
• 63463-36-5 (1-methyl-4-piperidyl)magnesium chloride 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 107285-30-3 3-<2-(3-chlorophenyl)ethyl>-N-(1,1-dimethylethyl)-2-pyridinecarboxamide 
• 32998-95-1 N-tert-butyl-3-methylpyridine-2-carboxamide 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 79794-75-5 loratadine 

Relevant articles and documents

Preparation method of loratadine

The invention provides a preparation method of loratadine. The method comprises the following steps: taking 2-cyano-3-methylpyridine as a raw material, and carrying out Ritter reaction, m-chlorobenzylchloride condensation, POCl3 deprotection group, Grignard reaction, cyclization and ethyl chloroformate substitution to obtain 4(8-chlorine-5, 6-dihydro-11H-benzo-[5, 6]cycloheptano[1, 2-b]pyridine-11-subunit)-1-piperidine carboxylic acid ethyl ester. According to the invention, a post-treatment process is innovated, and a new cyclization system is adopted to catalyze the reaction, so that the use of high-cost and high-toxicity strong acid is avoided, and a milder and more economical synthesis method is provided for industrial production.

Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 Also disclosed are novel compounds of the formulas: Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: STR1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R20)(R21)(R46), and 5.3, 5.3A and 5.3B, wherein R is --N(R25)(R48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.